AMBUJACEM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 2.7
| Stock Code | AMBUJACEM | Market Cap | 1,03,828 Cr. | Current Price | 420 ₹ | High / Low | 625 ₹ |
| Stock P/E | 29.0 | Book Value | 206 ₹ | Dividend Yield | 0.48 % | ROCE | 8.80 % |
| ROE | 8.77 % | Face Value | 2.00 ₹ | DMA 50 | 498 ₹ | DMA 200 | 538 ₹ |
| Chg in FII Hold | -0.11 % | Chg in DII Hold | 0.23 % | PAT Qtr | 227 Cr. | PAT Prev Qtr | 1,571 Cr. |
| RSI | 26.4 | MACD | -25.1 | Volume | 28,31,852 | Avg Vol 1Wk | 40,86,182 |
| Low price | 418 ₹ | High price | 625 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.02 |
| 52w Index | 0.82 % | Qtr Profit Var | -87.1 % | EPS | 13.7 ₹ | Industry PE | 27.0 |
📊 AMBUJACEM shows weak technicals for intraday trading. RSI at 26.4 indicates oversold conditions, but MACD remains negative (-25.1), suggesting bearish momentum. Current price (420 ₹) is well below both 50 DMA (498 ₹) and 200 DMA (538 ₹), reflecting sustained weakness. Intraday volume (28.3L) is lower than the 1-week average (40.8L), showing reduced participation, which limits strong intraday moves.
💡 Optimal Buy Price: 415–425 ₹ (near support zone)
🎯 Profit-Taking Levels: 440–455 ₹ (short-term resistance)
🛑 Stop-Loss: 410 ₹ (recent low)
⏱️ If already holding: Exit near 440–450 ₹ if momentum stalls or volume weakens, as upside is capped by resistance and negative MACD.
Positive
- Reasonable P/E of 29 compared to industry PE (27.0).
- Strong book value of 206 ₹ provides valuation support.
- Low debt-to-equity ratio (0.02) ensures financial stability.
- DII holdings increased by 0.23%, showing domestic investor confidence.
Limitation
- Stock trading below both 50 DMA and 200 DMA confirms bearish trend.
- Quarterly PAT declined sharply (227 Cr vs 1,571 Cr), showing earnings pressure.
- Weak ROCE (8.80%) and ROE (8.77%) highlight poor capital efficiency.
- FII holdings decreased by 0.11%, showing reduced foreign investor confidence.
Company Negative News
- No major external negative news reported, but quarterly profit decline (-87.1%) is a significant concern.
Company Positive News
- EPS at 13.7 ₹ supports profitability despite weak quarter.
- Dividend yield of 0.48% provides shareholder returns.
Industry
- Industry PE at 27.0 is slightly lower than company PE (29.0), suggesting AMBUJACEM trades at a small premium.
- Cement sector remains steady, but AMBUJACEM underperforms due to weak earnings momentum.
Conclusion
⚖️ AMBUJACEM is fundamentally fair but technically weak for intraday trades today. Entry near 415–425 ₹ with a stop-loss at 410 ₹ is advisable only for cautious traders. Upside potential is limited to 440–455 ₹, making it a risky intraday candidate rather than a strong buy.